Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The refinement of genetic predictors of multiple sclerosis.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate
Trial watch: Chemotherapy with immunogenic cell death inducers.
A bacterial metabolite induces glutathione-tractable proteostatic damage, proteasomal disturbances, and PINK1-dependent autophagy in C. elegans.
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Intermittent Atrioventricular Block following Fingolimod Initiation.
Ustekinumab approved for psoriatic arthritis in US, Europe
Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
The validity and reliability of the neurogenic bladder symptom score (NBSS).
[Unified assessment of adverse events of multiple sclerosis disease modifying drugs.]
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
Neuromyelitis optica: clinical manifestations and neuroimaging features.
Accelerated repair of demyelinated CNS lesions in the absence of non-muscle myosin IIB.
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.
Simvastatin: two decades in a circle.
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
White matter atrophy and cognitive dysfunctions in neuromyelitis optica.
The role of tumour necrosis factor α in the pathogenesis of multiple sclerosis, and pentoxifylline as a possible pharmacotherapeutic intervention.
Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
UCSF Neuroimmunology Seminar

Pages